Vividion Therapeutics, a biotechnology company that launched in 2017 around discoveries made in Scripps Research Institute labs, has raised $82 million in financing.

Nextech Invest, a Swiss investment firm that funds companies developing cancer therapeutics, led the Series B round of funding. As part of the investment, Nextech partner Jakob Loven gets a board seat.

The company’s technology is based on work from the labs of Benjamin Cravatt, Phil Baran, and Jin-Quan Yu in La Jolla, CA, where Scripps is based.

The company aims to discover and develop new drugs that can treat disease by modulating protein levels by using a… Read more »